A Unique Healthcare Play

Published on
May 10th, 2018
Duration
8 minutes

A Unique Healthcare Play

Trade Ideas ·
Featuring Louis Llanes

Published on: May 10th, 2018 • Duration: 8 minutes

Louis Llanes, Founder Of Wealthnet Investments, is betting on healthcare R&D firm IQVIA. He discusses his trade idea in this interview with Justine Underhill. Filmed on May 3, 2018.

Comments

  • LA
    Linda A.
    26 July 2018 @ 17:33
    lol at end- gotta love Louis!
  • SS
    Sophocles S.
    17 May 2018 @ 08:02
    Bring in more people like Louis!
    • LL
      Louis L. | Contributor
      25 May 2018 @ 01:13
      Thank you! I’ll do my best to bring good ideas our team thinks will make money.
  • SH
    Syed H.
    13 May 2018 @ 18:33
    Great interview Justine. Keep it up.
  • JW
    John W.
    12 May 2018 @ 11:39
    Hey Louis, great analysis - I love your use of VWAP. These in-depth reviews are what I am here to see, and you are quickly becoming one of my favorites to watch here on RV. Side note - Quintiles was right here in my back yard in Cary NC.
    • LL
      Louis L. | Contributor
      14 May 2018 @ 20:05
      Thank you
  • MS
    Michele S. | Contributor
    11 May 2018 @ 14:35
    As a fellow interviewee, I enjoyed your analysis (and pick)-I only wish I had seen it early yesterday for an entry around 99-up over $3.50 in a day-nevertheless, you are now on my radar.
  • KF
    Karen F.
    11 May 2018 @ 12:03
    In my point of view too much goodwill and debt on the balancesheet. Certainly for an outsource company.
    • LL
      Louis L. | Contributor
      11 May 2018 @ 13:47
      Goodwill is from merger. What’s more important is valuation on cash flows, not historical based book values which have less relationship to the valuation of the enterprise. This is not a company you would value based on net tangible book value in our view. That’d be appropriate for an asset rich company with little to no growth in cash flows.
  • GS
    Geoff S.
    10 May 2018 @ 19:39
    Interesting idea. Would love to hear more about the merger and how it has created the perceived competitive advantage. Also no word on valuation, unfortunately. It would be great if RV could capture those angles in its line of questioning with the money managers. Far more useful than stop loss/target prices, etc., which are less relevant to longer term investors.
    • EF
      Eric F.
      11 May 2018 @ 00:10
      To be fair, it’s trade ideas so if something catches your interest you can do the research / due diligence required.
    • ML
      Michael L.
      13 May 2018 @ 01:05
      Agree, especially since he mentioned competitive advantage a few times, he really should have spent 10 seconds talking about what those are. Just citing a high level theme like "increased R&D spending" and show some charts is not analysis. No mention of growth potential, upside to earnings...etc. Some of the luminaries that RV interviewed - Bass, Hempton, Cohodes..etc would totally tear this apart
    • LL
      Louis L. | Contributor
      14 May 2018 @ 03:36
      The format of this is fast. The competence advantages comes from technology and databases from the merger that allows IQV to deliver outsourced R&D quicker and more effectively with Phase 2-4 trials. This has led to sticky Client relationships. Their customers have switching costs to go elsewhere or take it on internally. I alluded to this in presentation. Hope you keep watching and I’ll keep that in mind for you in later recordings.